Diagnostics firm Indi snags $47.3M for lung tests

Seattle startup Integrated Diagnostics, or Indi, picked up $47.3 million in equity and debt financing, money it'll use to expand the market for its lung nodule-diagnosing test. Under the financing deal, Indi raised $30.3 million in Series B money from investors including Baird Capital, InterWest Partners and the Wellcome Trust, and separately secured a $17 million debt facility from Life Sciences Alternative Funding. Now, the company is planning to amp up marketing for its Xpresys test, designed to cheaply determine whether lung growths are benign, ruling out costlier biopsies and saving money for patients and providers. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.